Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Trends in Biotechnology|April 9, 2021
Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell TherapiesRocío Castellanos-Rueda, Raphaël B Di Roberto, Fabrice S Schlatter, et al.
Molecular Therapy. Methods & Clinical Development|July 14, 2023
A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell transfer applicationsDarya Palianina, Raphaël B Di Roberto, Rocío Castellanos-Rueda, et al.
Science Advances|February 14, 2025
Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencingRocío Castellanos-Rueda, Kai-Ling K Wang, Juliette L Forster, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 23, 2020
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor ActivationRaphaël B Di Roberto, Rocío Castellanos-Rueda, Samara Frey, et al.
Communications Biology|January 5, 2021
Exploiting genetic diversity and gene synthesis to identify superior nitrogenase NifH protein variants to engineer N2-fixation in plantsXi Jiang, Lucía Payá-Tormo, Diana Coroian, et al.
Mbio|June 13, 2022
Functional Nitrogenase Cofactor Maturase NifB in Mitochondria and Chloroplasts of Nicotiana benthamianaXi Jiang, Diana Coroian, Emma Barahona, et al.
Nature Communications|October 2, 2021
A rational blueprint for the design of chemically-controlled protein switchesSailan Shui, Pablo Gainza, Leo Scheller, et al.
Nature Communications|November 3, 2022
speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencingRocío Castellanos-Rueda, Raphaël B Di Roberto, Florian Bieberich, et al.
Nature Chemical Biology|February 19, 2026
Drug-controlled CAR T cells through the regulation of cell-cell interactionsLeo Scheller, Greta Maria Paola Giordano Attianese, Rocío Castellanos-Rueda, et al.
Nature Biomedical Engineering|September 25, 2024
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodiesEdo Kapetanovic, Cédric R Weber, Marine Bruand, et al.
Pageof 2